Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease
Main finding · Non-fatal MI or stroke, T2D and CKDResult — go to the resultHazard ratio 0.86 95% CI 0.78–0.94Authors' conclusion
Recognizing the potential for residual confounding, selection bias and immortal time bias, commercially insured patients in the United States with T2DM and CKD treated with SGLT-2 inhibitors experienced significantly lower risks of non-fatal myocardial infarction or stroke relative to those treated with GLP-1 receptor agonists.
Study context
- Population
- Commercially insured US adults with T2D and chronic kidney disease (CKD) (Optum Clinformatics DataMart 2003–2021)
- Exposure
- SGLT2i vs GLP-1 RA
- Outcome
- Non-fatal MI or stroke
Methodological detailsnew-user design, inverse probability of treatment weighting
- New-user design
- Inverse probability of treatment weighting
Main finding
Non-fatal MI or stroke, T2D and CKD
Hazard ratio
0.86
95% CI 0.78–0.94
SGLT-2 inhibitorsvs GLP-1 receptor agonists
HR 0.86 (95% CI 0.78–0.94)
As reported in the abstract
Observational data: associations, not effects.
Original publication
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease. Diabetes Obes Metab. Published 8 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →